War is a part of human nature. It’s the greatest driver of human innovation, and if we’re inclined to be cynical we could state that it’s the key reason…
mushrooms
This week’s digest of mushroom moves is a mixed bag of trash and glory, with the shrooms sector increasingly looking like the early days of the cannabis rush….
Mydecine Innovations Group (MYCO.C) signed a non-binding letter of intent to acquire NeuroPharm, a Canadian-based healthcare company involved in the nascent shroom-space earlier this week. The all-share deal will…
Graph Blockchain (GBLC.C) is rolling out an e-commerce wellness marketplace platform and subsidiary, BluStem, during the week of June 1, 2020. BluStem is an e-commerce marketplace for business to…
A randomized, double-blind trial from Johns Hopkins in 2016 found that a single dose of psilocybin substantially improved quality of life and decreased depression and anxiety in people with…
Revive Therapeutics is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (Covid-19)…
There’s a fair amount of excitement bubbling up over the potential for a market in psychedelics. Mostly, we’re hearing about psilocybin and psilocin, the active psychedelic components in magic…
A cannabis company producing another build-out, another dispensary or pushing forward incrementally isn’t what necessarily passes newsworthy muster. This isn’t 2017 anymore, and it’s generally assumed that most companies…
Hollister Biosciences (HOLL.C) is normally a cannabis company. They have products in 220 dispensaries throughout California, and now they have caught wind that mushrooms might be the next big…
The long and short of it is that psychedelics aren’t here yet. There are plenty of companies in various stages of development, doing what they can to make various…